Voluntis is a technology company.
Voluntis has raised $3.0M across 1 funding round.
Voluntis has raised $3.0M in total across 1 funding round.
Voluntis has raised $3.0M in total across 1 funding round.
Voluntis's investors include Karista.
Voluntis is a digital therapeutics company that develops software solutions empowering patients with chronic conditions, particularly in oncology and diabetes, to self-manage treatments via mobile and web apps.[1][2][3] Its Theraxium platform delivers personalized clinical recommendations to patients and care teams, addressing side effects, adherence, and outcomes to improve real-world results for individuals and support pharma reimbursement needs.[1][3] Headquartered in Paris (Suresnes) and Cambridge, MA, with around 100 employees and $21.1M revenue, Voluntis serves healthcare organizations and life science partners, showing growth through $7.4M total funding and a 2023 majority acquisition by Aptar at €8.70 per share.[2][5]
Founded in 2001 in Suresnes, France, Voluntis pioneered digital therapeutics focused on enhancing patient treatment experiences for chronic conditions.[5][2] The company evolved from Patient Relationship Management (PRM) software to specialized digital therapeutics, leveraging long-standing partnerships with leading life science firms and becoming a founding member of the Digital Therapeutics Alliance.[3][4] Key milestones include Debiopharm's 2020 investment, betting on digital companions for oncology drugs to manage side effects and boost adherence, and Aptar's acquisition of a majority stake, signaling strong validation in the sector.[1][2]
Voluntis rides the digital therapeutics wave, where software as medical devices addresses chronic disease burdens amid rising cancer and diabetes prevalence.[1][3] Timing aligns with pharma's push for real-world evidence to secure reimbursements, as all oncology drugs increasingly pair with digital companions for side-effect management and adherence.[1] Market forces like aging populations, value-based care, and post-acquisition scale from Aptar favor Voluntis, influencing the ecosystem by setting standards for patient-centric PRM and accelerating hybrid drug-digital models.[2][3]
Voluntis is poised for expansion under Aptar, likely scaling Theraxium-powered therapeutics beyond oncology/diabetes into new chronic areas with deeper pharma integrations.[2] Trends like AI-enhanced personalization and global reimbursement for digital health will propel growth, evolving its role from innovator to ecosystem enabler. As digital companions become standard, Voluntis' early-mover status positions it to drive better patient outcomes at the intersection of software and chronic care.[1][3]
Voluntis has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Venture Round in January 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2007 | $3.0M Venture Round | Karista |